These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 33845122)

  • 1. Intestinal microbiota: A potential target for enhancing the antitumor efficacy and reducing the toxicity of immune checkpoint inhibitors.
    Luo B; Zhang Y; Zhang C; Liu X; Shi C
    Cancer Lett; 2021 Jul; 509():53-62. PubMed ID: 33845122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics.
    Zhang J; Dai Z; Yan C; Zhang W; Wang D; Tang D
    Clin Transl Oncol; 2021 Dec; 23(12):2415-2430. PubMed ID: 34125407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer.
    Hayase E; Jenq RR
    Genome Med; 2021 Jun; 13(1):107. PubMed ID: 34162429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.
    Rezasoltani S; Yadegar A; Asadzadeh Aghdaei H; Reza Zali M
    Cancer Med; 2021 Feb; 10(3):1141-1154. PubMed ID: 33369247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy.
    Tian M; Zhang S; Tseng Y; Shen X; Dong L; Xue R
    Anticancer Agents Med Chem; 2022; 22(7):1244-1256. PubMed ID: 34229597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.
    Wu J; Wang S; Zheng B; Qiu X; Wang H; Chen L
    Front Immunol; 2021; 12():669150. PubMed ID: 34267748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy.
    Huang J; Jiang Z; Wang Y; Fan X; Cai J; Yao X; Liu L; Huang J; He J; Xie C; Wu Q; Cao Y; Leung EL
    Curr Opin Pharmacol; 2020 Oct; 54():1-10. PubMed ID: 32619934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Challenge of ICIs Resistance in Solid Tumours: Could Microbiota and Its Diversity Be Our Secret Weapon?
    Roberto M; Carconi C; Cerreti M; Schipilliti FM; Botticelli A; Mazzuca F; Marchetti P
    Front Immunol; 2021; 12():704942. PubMed ID: 34489956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of gut microbiota in regulating immune checkpoint inhibitor therapy for glioblastoma.
    Zhang H; Hong Y; Wu T; Ben E; Li S; Hu L; Xie T
    Front Immunol; 2024; 15():1401967. PubMed ID: 38915399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in Cancer.
    Chang AE; Golob JL; Schmidt TM; Peltier DC; Lao CD; Tewari M
    Trends Cancer; 2021 Jul; 7(7):583-593. PubMed ID: 33741313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tying Small Changes to Large Outcomes: The Cautious Promise in Incorporating the Microbiome into Immunotherapy.
    Chau J; Zhang J
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut microbiota interactions with antitumor immunity in colorectal cancer: From understanding to application.
    Zhuang YP; Zhou HL; Chen HB; Zheng MY; Liang YW; Gu YT; Li WT; Qiu WL; Zhou HG
    Biomed Pharmacother; 2023 Sep; 165():115040. PubMed ID: 37364479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect.
    Xia L; Zhu X; Wang Y; Lu S
    Cancer Lett; 2024 Aug; 598():217123. PubMed ID: 39033797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges.
    Bouferraa Y; Chedid A; Amhaz G; El Lakkiss A; Mukherji D; Temraz S; Shamseddine A
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Association between Immunotherapy with Immune Checkpoint Inhibitors(Anti-PD-1 Antibodies)and Intestinal Microbiota].
    Ozaki Y; Suzuki Y; Nishiyama K; Suzutani T; Suzuki H
    Gan To Kagaku Ryoho; 2021 Sep; 48(9):1096-1099. PubMed ID: 34521783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite.
    Renga G; Nunzi E; Pariano M; Puccetti M; Bellet MM; Pieraccini G; D'Onofrio F; Santarelli I; Stincardini C; Aversa F; Riuzzi F; Antognelli C; Gargaro M; Bereshchenko O; Ricci M; Giovagnoli S; Romani L; Costantini C
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35236743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling.
    Shi Y; Zheng W; Yang K; Harris KG; Ni K; Xue L; Lin W; Chang EB; Weichselbaum RR; Fu YX
    J Exp Med; 2020 May; 217(5):. PubMed ID: 32142585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intestinal microbiom modulates the response to antitumor immunotherapy].
    Olekhnovich EI; Manolov AI; Pavlenko AV; Konanov DN; Fedorov DE; Tikhonova PO; Glushchenko OE; Ilina EN
    Biomed Khim; 2020 Jan; 66(1):54-63. PubMed ID: 32116226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between gut microbiota and immune checkpoint inhibitor-related colitis.
    Zhou G; Zhang N; Meng K; Pan F
    Front Immunol; 2022; 13():1001623. PubMed ID: 36389768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors.
    Simpson RC; Shanahan ER; Scolyer RA; Long GV
    Nat Rev Clin Oncol; 2023 Oct; 20(10):697-715. PubMed ID: 37488231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.